ClinicalTrials.gg
CompletedNCT06077786Updated Jun 28, 2024

A Trial Investigating the Pain-relieving Properties of Lu AG06474 in Healthy Adult Participants

A Phase 1 interventional study of Lu AG06474 and Placebo to Lu AG06474 in Healthy Participants, sponsored by H. Lundbeck A/S. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-28.

Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main goal of this trial is to learn about the effect of Lu AG06474 on a battery of Evoked Pain Tests when a single dose is given to healthy adult participants. The effects of Lu AG06474 will be compared with 2 approved pain-relieving medications (ibuprofen and pregabalin) and with a placebo (a treatment that looks like the trial treatment but does not have any medicine in it). Each participant will receive 1 dose of each of these treatments during the trial (Lu AG06474, ibuprofen, pregabalin, and placebo), with 1 week between treatments. All treatments will be taken orally (by mouth), either as a liquid or a capsule.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has a (BMI) ≥18.5 and ≤32 kilograms per meter squared (kg/m\^2) at the Screening Visit and at the Trial Baseline Visit.
  • The participant is, in the opinion of the investigator, generally healthy based on medical history, a physical examination, a neurological examination, vital signs, an , and the results of the clinical chemistry, haematology, urinalysis, serology, and other laboratory tests.

Exclusion criteria

Exclusion Criteria:

  • The participant is a member of the site staff or of their immediate families or is a subordinate (or immediate family member of a subordinate) to any of the site staff.
  • The participant has Fitzpatrick skin type IV, V and VI, wide-spread acne, tattoos, or scarring interfering with the area of interest (that is, upper back).
  • The participant is currently enrolled in another clinical trial or used any drug or device within 3 months (or \<5 half-lives of that product, whichever is longer) prior to dose of investigational medicinal product (IMP), or has participated in more than 4 investigational drug studies within 1 year prior to Screening.
  • The participant takes any disallowed medication within 14 days from first dose of trial drug.
  • The participant has been vaccinated ≤14 days prior to the first dose of IMP.
  • The participant is pregnant, breastfeeding, intends to become pregnant, or is of child bearing potential and not willing to use adequate methods.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Part A: Lu AG06474 + Placebo

    Participants will receive a single dose of Lu AG06474 (oral solution) and a single dose of placebo (3 placebo capsules).

    Drug: Lu AG06474 · Drug: Placebo

  • Experimental
    Part B: Ibuprofen + Placebo to Lu AG06474

    Participants will receive a single dose of ibuprofen (3 ibuprofen capsules) and a single dose of placebo to Lu AG06474 (oral solution).

    Drug: Placebo to Lu AG06474 · Drug: Ibuprofen

  • Experimental
    Part C: Pregabalin + Placebo to Lu AG06474

    Participants will receive a single dose of pregabalin (1 capsule + 2 placebo capsules) and a single dose of placebo to Lu AG06474 (oral solution).

    Drug: Placebo to Lu AG06474 · Drug: Pregabalin · Drug: Placebo

  • Experimental
    Part D: Placebo to Lu AG06474 + Placebo

    Participants will receive a single dose of placebo to Lu AG06474 (oral solution) and a single dose of placebo (3 placebo capsules).

    Drug: Placebo to Lu AG06474 · Drug: Placebo

Interventions

  • DrugLu AG06474

    Oral solution

  • DrugPlacebo to Lu AG06474

    Oral solution

  • Capsule

  • Capsule

  • DrugPlacebo

    Capsule

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Pain Detection Thresholds (PDTs) for the UVB Heat Pain Test

    The PDT is the degrees Celsius where the participant first detects pain.

    Time frame: Baseline to 6 hours post-dose

  2. Change From Baseline in Pain Detection Thresholds (PDTs) for the Capsaicin Heat Pain Test

    The PDT is the degrees Celsius where the participant first detects pain.

    Time frame: Baseline to 6 hours post-dose

  3. Change From Baseline in Area of Secondary Mechanical Allodynia After the Capsaicin Challenge

    The area of secondary mechanical allodynia will be reported for the capsaicin challenge, measured in squared millimeters (mm\^2).

    Time frame: Baseline to 6 hours post-dose

  4. Change From Baseline in Pain Tolerance Thresholds (PTTs) for the Cold Pressor Test

    The PTT is the timepoint (in seconds) where the participant can no longer tolerate the pain.

    Time frame: Baseline to 6 hours post-dose

  5. Change From Baseline in Pain Detection Thresholds (PDTs) for the Cold Pressor Test

    The PDT is the timepoint (in seconds) where the participant first detects the pain.

    Time frame: Baseline to 6 hours post-dose

Secondary outcomes

  1. AUC0-8h: Area Under the Curve Concentration-time Curve from Zero to 8 hours Post-dose

    Time frame: 0 (predose) to 8 hours postdose on Day 1 to Day 22

  2. Cmax: Maximum Observed Plasma Concentration

    Time frame: 0 (predose) to 8 hours postdose on Day 1 to Day 22

  3. tmax: Nominal Time Corresponding to the Occurrence of Cmax

    Time frame: 0 (predose) to 8 hours postdose on Day 1 to Day 22

  4. Difference to Placebo in Blood Levels of Endocannabinoids

    Time frame: 0 (predose) to 8 hours postdose on Day 1 to Day 22

07

Study locations

1 site
  • Centre for Human Drug Research
    Leiden, 2333 CL, Netherlands
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in May 2024, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2023
First posted
Oct 11, 2023
StartActual
Oct 13, 2023
Primary completionActual
May 10, 2024
CompletionActual
May 17, 2024
Last update
Jun 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06077786
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Oct 11, 2023
Start date
Oct 13, 2023
Primary completion
May 10, 2024
Completion
May 17, 2024
Last update
Jun 28, 2024

Study contacts

Email contact via H. Lundbeck A/S
study director · H. Lundbeck A/S

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Pregabalin

Start the discussion